ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.685,32
-0,22%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,084
-0,14%
Bitcoin
70.125,65
-0,01%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. PhenomeX Inc (CELL)

  7. PhenomeX Inc (CELL) News

CELL

PhenomeX (CELL)

PhenomeX Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CELL
DatumZeitQuelleÜberschriftSymbolFirma
08/02/202423h58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CELLPhenomeX Inc
12/10/202315h00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:CELLPhenomeX Inc
03/10/202321h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CELLPhenomeX Inc
03/10/202321h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CELLPhenomeX Inc
03/10/202320h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CELLPhenomeX Inc
02/10/202323h16Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:CELLPhenomeX Inc
02/10/202323h06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CELLPhenomeX Inc
02/10/202323h05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CELLPhenomeX Inc
02/10/202323h04Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CELLPhenomeX Inc
02/10/202323h03Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CELLPhenomeX Inc
02/10/202323h02Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:CELLPhenomeX Inc
02/10/202314h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELLPhenomeX Inc
29/09/202314h30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:CELLPhenomeX Inc
27/09/202314h51PR Newswire (US)PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic PlatformNASDAQ:CELLPhenomeX Inc
21/09/202314h35PR Newswire (US)PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development WorkflowsNASDAQ:CELLPhenomeX Inc
20/09/202314h48PR Newswire (US)PhenomeX to Participate in Upcoming Cell Biology ConferencesNASDAQ:CELLPhenomeX Inc
20/09/202312h05Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:CELLPhenomeX Inc
15/09/202315h08PR Newswire (US)PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free ProteomicsNASDAQ:CELLPhenomeX Inc
05/09/202322h02PR Newswire (US)PhenomeX Inc. Announces Commencement of Cash Tender Offer by BrukerNASDAQ:CELLPhenomeX Inc
31/08/202322h47Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:CELLPhenomeX Inc
28/08/202323h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CELLPhenomeX Inc
18/08/202323h21Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CELLPhenomeX Inc
17/08/202323h28Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CELLPhenomeX Inc
17/08/202323h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELLPhenomeX Inc
17/08/202315h10Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CELLPhenomeX Inc
17/08/202315h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELLPhenomeX Inc
17/08/202315h00Business WireBruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash TransactionNASDAQ:CELLPhenomeX Inc
14/08/202322h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CELLPhenomeX Inc
14/08/202322h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELLPhenomeX Inc
14/08/202322h05PR Newswire (US)PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CELLPhenomeX Inc
 Showing the most relevant articles for your search:NASDAQ:CELL

Kürzlich von Ihnen besucht

LSE
0MGR
Forvia
LSE
SBAB
Ls -1x Alibaba
COIN
KNDCBTC
KanadeCoin
USOTC
SRAIF
Stadler Rail (PK)
NYSE
SYF
Synchrony Financiall
COIN
CRNUSD
ASX
CCQ
Contango Capital Partners
COIN
BIRGBP
LSE
PKP
BITV
STXEUR
Stacks
COIN
MODXGBP
NASDAQ
CSAXX
Cash Account Trust
DBI
I1NZ
Xtr MSCI Emerging Market...
USOTC
SNGWF
SG Issuer (GM)
NYSE
NHA
Nuveen Municipal 2021 Ta...
COIN
GUSEUR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten